Anixa Biosciences
115 articles about Anixa Biosciences
-
Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant
8/25/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2.
-
Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer Initiative
8/23/2021
Anixa Biosciences, Inc. announced today that Director, Dr. Arnold Baskies has been appointed to the World Health Organization's (WHO) Global Breast Cancer Initiative.
-
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology
8/18/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office has issued the first U.S. patent for its novel ovarian cancer vaccine technology.
-
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
5/26/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that its ovarian cancer vaccine technology is part of an award from the National Cancer Institute (NCI).
-
Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application
5/20/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy
-
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
5/7/2021
OntoChem GmbH, a German Life Science IT company, announced that it has assigned its drug discovery technologies and assets, including its drug discovery collaboration with Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, to the newly formed MolGenie GmbH, a biotech company focusing on drug discovery and development.
-
Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy
4/19/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has requested additional information regarding its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Cancer Center (MCC)
-
The government agency is asking for more information before approving a clinical study on the company’s Chimeric Antigen Receptor-T cell therapy (CAR-T).
-
Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic
4/5/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that based on Proof of Concept (POC) animal study results, it will progress to the next stage of development of its potential anti-viral therapy for Covid-19.
-
Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million
3/23/2021
Anixa Biosciences, Inc., a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 4,285,715 shares of common stock of the Company at a public offering price of $5.25 per share, less underwriting discounts and commissions.
-
Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
3/22/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration
-
Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
3/22/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis
-
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
3/12/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent
-
Anixa Biosciences to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
3/8/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Anixa's Chief Executive Officer, Dr. Amit Kumar, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.
-
Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy
3/4/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued the first European patent for Anixa's novel CAR-T cancer treatment technology, which has been licensed from The Wistar Institute
-
Anixa Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference
2/25/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.
-
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
2/16/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that animal testing has commenced with two proprietary compounds that have shown potency in in vitro studies.
-
Anixa Biosciences to Present at the B. Riley Oncology Investor Conference
1/13/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at B. Riley's Inaugural Oncology Investor Conference to be held January 20-21 , 2021.
-
Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
1/5/2021
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14 , 2021.
-
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing
12/14/2020
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem GmbH have verified that one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug agains